Re: Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia

Steven A. Kaplan

Research output: Contribution to journalComment/debate

Original languageEnglish
Pages (from-to)1758-1759
Number of pages2
JournalJournal of Urology
Volume187
Issue number5
DOIs
StatePublished - May 2012

Cite this